Delivery Order SPE2DB22D3301-SPE2DB26FX3LS
- Not listed
- The Defense Logistics Agency awarded a $23,543.70 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and is scheduled for completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- The Defense Logistics Agency awarded a $26,156.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit of use packaging) on September 24, 2025, with completion targeted for September 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a $35,816.58 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. Performance will be executed from the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $20,682.34 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to compete...
- The Defense Logistics Agency awarded a $28,684.94 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price delivery order, which is set to be completed by September 4, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a $12.8K delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 12, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency awarded a $28,065.03 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of RINVOQ ER 15 mg tablets in units of 30. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of RINVOQ ER 30 mg tablets in quantities of 30 units. This is a competitively awarded, firm fixed-price delivery order with a ceiling value of $19,727.87 and an ultimate completion date of July 24, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3LSDelivery Order
The Defense Logistics Agency awarded a $228,081.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 17, 2025, for the supply of RINVOQ ER 45 MG tablets (28-count units). This is a non-set-aside competitive award with an ultimate completion date of October 20, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen is a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, and serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Vehicle (SPE2DX) valued at $999,999,999.00 and running through December 2026, which provides comprehensive global pharmaceutical support to military healthcare programs. The contract vehicle enables the company to supply a broad range of pharmaceutical products, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. Performance will occur at the company's corporate office location in Conshohocken, Pennsylvania, with the company demonstrating capability to meet federal procurement requirements through consistent competitive award outcomes and substantial contract values across its portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $228.1k | 10/17/25 |